Related Experiment Video

Updated: Jun 9, 2026

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

Expanding phenotype and clinical analysis of tyrosine hydroxylase deficiency

Wai-Lan Yeung1, Virginia C N Wong, Kwok-Yin Chan

  • 1Department of Paediatrics, Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China. yw1221@ha.org.hk

Journal of Child Neurology
|September 9, 2010
PubMed

Insights

Tyrosine hydroxylase deficiency presents diverse phenotypes, from severe infantile encephalopathy to mild myopathy. Early levodopa treatment, with selegiline for severe cases, improves outcomes, especially in milder forms.

Area of Science:

  • Biochemistry
  • Genetics
  • Neurology

Background:

  • Tyrosine hydroxylase deficiency (THD) is a rare genetic disorder affecting neurotransmitter synthesis.
  • It leads to a spectrum of neurological symptoms, varying in severity and age of onset.

Purpose of the Study:

  • To characterize the clinical phenotypes of THD in Chinese patients.
  • To investigate the relationship between biochemical markers and clinical presentation.
  • To evaluate treatment responses and outcomes.

Main Methods:

  • Retrospective analysis of 12 Chinese patients with THD.
  • Clinical phenotyping, including age of onset and symptom spectrum.
  • Cerebrospinal fluid (CSF) analysis for homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA).
  • Assessment of treatment response to levodopa and selegiline.

Main Results:

  • Phenotypes ranged from severe infantile encephalopathy/parkinsonism to mild dopa-responsive dystonia/myopathy.
  • Severe phenotypes were associated with HVA and HVA/5-HIAA ratio < 1 in CSF.
  • Female siblings often exhibited more severe symptoms.
  • Levodopa was the primary treatment; early selegiline addition showed benefit in some severe cases.
  • Mild-type patients had universally good treatment response, even with delayed treatment.

Conclusions:

  • THD exhibits a wide phenotypic spectrum influenced by genetic and biochemical factors.
  • CSF HVA and HVA/5-HIAA ratio are valuable indicators for disease severity.
  • Timely and appropriate treatment, particularly levodopa and selegiline, can significantly improve patient outcomes.

More Related Videos

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area09:54

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area

Published on: August 10, 2012

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pedigree Analysis01:35

Pedigree Analysis

Overview
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...